利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

129 条记录 (耗时 0.03 秒)

    Methods employing generalized target-binding e-tag probes
    1.
    发明授权
    Methods employing generalized target-binding e-tag probes 有权
    使用广泛靶向结合电子标签探针的方法

    公开(公告)号：US06818399B2

    公开(公告)日：2004-11-16

    申请号：US09824984

    申请日：2001-04-02

    申请人： Sharat Singh ,  Hossein Salimi-Moosavi ,  Vivian Xiao

    发明人： Sharat Singh ,  Hossein Salimi-Moosavi ,  Vivian Xiao

    IPC分类号： C12O168

    CPC分类号： C07H19/06 ,  C07H19/10 ,  C07H21/00 ,  C40B70/00 ,  G01N33/561 ,  Y10S435/81

    摘要： Methods for the multiplexed detection of the binding of, or interaction between, one or more ligands and target antiligands are provided. Detection involves the release of identifying tags as a consequence of target recognition. The methods include the use of electrophoretic tag probes or e-tag probes, comprising a detection region and a mobility-defining region called the mobility modifier, both linked to a target-binding moiety. In practicing the methods, target antiligands are contacted with a set of e-tag probes and the contacted antiligands are treated with a selected cleaving agent resulting in a mixture of e-tag reporters and uncleaved and/or partially cleaved e-tag probes. The mixture is exposed to a capture agent effective to bind to uncleaved or partially cleaved e-tag probes, followed by electrophoretic separation. In a multiplexed assay, different released e-tag reporters may be separated and detected providing for target identification.

    摘要翻译： 提供了多个检测一种或多种配体和靶向反配位体的结合或相互作用的方法。 检测涉及到识别标签作为目标识别的结果。 所述方法包括使用电泳标签探针或电子标签探针，其包含与靶结合部分连接的检测区域和称为迁移率调节剂的迁移率限定区域。 在实施该方法时，将目标抗配糖与一组e-标签探针接触，并用选定的切割剂处理所接触的抗配糖，导致电子标签报告子与未切割和/或部分切割的e-标签探针的混合物。 将混合物暴露于有效结合未切割或部分切割的e-标签探针的捕获剂，然后进行电泳分离。 在多重测定中，可以分离和检测不同的释放的电子标签记录器，以提供目标识别。

    ErbB Surface Receptor Complexes as Biomarkers
    3.
    发明申请
    ErbB Surface Receptor Complexes as Biomarkers 审中-公开
    ErbB表面受体复合物作为生物标志物

    公开(公告)号：US20100291594A1

    公开(公告)日：2010-11-18

    申请号：US12689144

    申请日：2010-01-18

    申请人： Po-Ying CHAN-HUI ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

    发明人： Po-Ying CHAN-HUI ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

    IPC分类号： G01N33/574

    CPC分类号： G01N33/56905 ,  G01N33/6893

    摘要： The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译： 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面，本发明包括通过将这样的病症与在患者样品，特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面，本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法，包括存在或 不存在癌前状态，存在或不存在癌症状态，癌症预后或对治疗的反应性。 优选地，本发明的方法通过使用具有可释放分子标签的结合化合物来实现，所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后，分离标签被释放并与测定混合物分离，用于分析。

    Methods for detecting receptor complexes comprising PI3K
    4.
    发明授权
    Methods for detecting receptor complexes comprising PI3K 有权
    用于检测包含PI3K的受体复合物的方法

    公开(公告)号：US07648828B2

    公开(公告)日：2010-01-19

    申请号：US11041073

    申请日：2005-01-21

    申请人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

    发明人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

    IPC分类号： G01N33/574

    CPC分类号： G01N33/542 ,  G01N33/57492 ,  G01N33/6803 ,  G01N33/6842 ,  G01N33/6872 ,  G01N2333/485 ,  G01N2333/49 ,  G01N2800/52

    摘要： The invention is directed to a new class of biomarker in patient samples comprising dimers of ErbB cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of ErbB cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译： 本发明涉及包含ErbB细胞表面膜受体的二聚体的患者样品中的新一类生物标志物。 在一个方面，本发明包括通过将这样的病症与在患者样品，特别是固定组织样品中直接测量的一种或多种ErbB细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面，本发明包括通过将样本细胞中的ErbB细胞表面膜受体的一种或多种二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症状态的方法，包括存在或 不存在癌前状态，存在或不存在癌症状态，癌症预后或对治疗的反应性。 优选地，本发明的方法通过使用具有可释放分子标签的结合化合物来实现，所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后，分离标签被释放并与测定混合物分离，用于分析。

    Surface Receptor Complexes as Biomarkers
    5.
    发明申请
    Surface Receptor Complexes as Biomarkers 审中-公开
    表面受体复合物作为生物标志物

    公开(公告)号：US20090111127A1

    公开(公告)日：2009-04-30

    申请号：US11866293

    申请日：2007-10-02

    申请人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

    发明人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

    IPC分类号： G01N33/574 ,  C12Q1/02 ,  G01N33/53

    CPC分类号： G01N33/57492 ,  G01N33/542 ,  G01N2333/485

    摘要： The invention is directed to a new class of biomarker in patient samples comprising dimers of cell surface membrane receptors. In one aspect, the invention includes a method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more dimers of cell surface membrane receptors measured directly in a patient sample, in particular a fixed tissue sample. In another aspect, the invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more dimers of cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译： 本发明涉及包含细胞表面膜受体二聚体的患者样品中的新一类生物标志物。 在一个方面，本发明包括通过将这样的病症与在患者样品，特别是固定组织样品中直接测量的一种或多种细胞表面膜受体的二聚体的量相关联来确定疾病或健康状况的状态的方法。 另一方面，本发明包括通过将样本细胞中的一种或多种细胞表面膜受体的二聚体的量的测量值与这样的状态相关联来确定来自个体的样品中癌症的状态的方法，包括存在或不存在 癌前状态，癌症状态的存在或不存在，癌症的预后或对治疗的反应性。 优选地，本发明的方法通过使用具有可释放分子标签的结合化合物来实现，所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后，分离标签被释放并与测定混合物分离，用于分析。

    METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS
    7.
    发明申请
    METHODS AND COMPOSITIONS FOR ANALYZING PROTEINS 审中-公开
    分析蛋白质的方法和组合物

    公开(公告)号：US20080311674A1

    公开(公告)日：2008-12-18

    申请号：US11837427

    申请日：2007-08-10

    申请人： Sharat Singh ,  Hossein Salimi-Moosavi ,  Syed Hasan Tahir ,  Gerald J. Wallweber ,  Hrair Kirakossian ,  Tracey J. Matray ,  Vincent S. Hernandez

    发明人： Sharat Singh ,  Hossein Salimi-Moosavi ,  Syed Hasan Tahir ,  Gerald J. Wallweber ,  Hrair Kirakossian ,  Tracey J. Matray ,  Vincent S. Hernandez

    IPC分类号： G01N27/26 ,  G01N33/53

    CPC分类号： G01N33/6842 ,  C07K16/00 ,  C07K2317/40 ,  G01N33/582 ,  G01N33/6803

    摘要： Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide. The interaction between the first binding agent and the binding site brings the cleavage-inducing moiety into close proximity to a cleavable moiety, which is associated with the polypeptide and is susceptible to cleavage only when in proximity to the cleavage-inducing moiety. In this way, an electrophoretic tag for each of the polypeptides may be released. Released electrophoretic tags are separated and the presence and/or amount of the target polypeptides are determined based on the corresponding electrophoretic tags.

    摘要翻译： 公开了用于确定样品中一种或多种靶多肽已经经历了翻译后修饰的方法，组合物和试剂盒。 包含样品和包含切割诱导部分的第一试剂和用于靶多肽上的结合位点的第一结合剂的混合物经受各自结合部分的结合发生的条件。 结合位点是涉及靶多肽的翻译后修饰活性的结果。 该方法可用于确定靶多肽本身。 在另一个实施方案中，靶多肽的存在和/或量与试剂例如涉及靶多肽的翻译后修饰的酶的存在和/或量和/或活性有关。 第一结合剂和结合位点之间的相互作用使切割诱导部分紧密接近可切割部分，其可与多肽相关，并且仅在接近切割诱导部分时易于切割。 以这种方式，可以释放每个多肽的电泳标签。 分离释放的电泳标签，并且基于相应的电泳标签确定靶多肽的存在和/或量。

    ERBB HETERODIMERS AS BIOMARKERS
    8.
    发明申请
    ERBB HETERODIMERS AS BIOMARKERS 审中-公开
    ERBB HETERODIMERS作为生物标记

    公开(公告)号：US20080187948A1

    公开(公告)日：2008-08-07

    申请号：US11965659

    申请日：2007-12-27

    申请人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

    发明人： Po-Ying Chan-Hui ,  Rajiv Dua ,  Ali Mukherjee ,  Sailaja Pidaparthi ,  Hossein Salimi-Moosavi ,  Yining Shi ,  Sharat Singh

    IPC分类号： C12Q1/02 ,  G01N33/50

    CPC分类号： G01N33/542 ,  G01N33/57492 ,  G01N2333/485

    摘要： A method of determining the status of a disease or healthful condition by correlating such condition to amounts of one or more heterodimers of ErbB, or Her, cell surface membrane receptors measured directly in a patient sample is described. The invention includes a method of determining a status of a cancer in a specimen from an individual by correlating measurements of amounts of one or more heterodimers of ErbB cell surface membrane receptors in cells of the specimen to such status, including presence or absence of a pre-cancerous state, presence or absence of a cancerous state, prognosis of a cancer, or responsiveness to treatment. Preferably, methods of the invention are implemented by using sets of binding compounds having releasable molecular tags that are specific for multiple components of one or more types of receptor dimers. After binding, molecular tags are released and separated from the assay mixture for analysis.

    摘要翻译： 描述了通过将这样的条件与直接在患者样品中测量的ErbB或Her的细胞表面膜受体的一个或多个异源二聚体的量相关联来确定疾病状态或健康状况的方法。 本发明包括通过将样品细胞中ErbB细胞表面膜受体的一个或多个异源二聚体的量的测量值与这样的状态相关联来确定来自个体的样本中癌症的状态的方法，包括存在或不存在前体 - 癌症状态，癌症状态的存在或不存在，癌症的预后或对治疗的反应性。 优选地，本发明的方法通过使用具有可释放分子标签的结合化合物来实现，所述组合化合物对于一种或多种类型的受体二聚体的多种组分是特异性的。 结合后，分离标签被释放并与测定混合物分离，用于分析。

    Methods and compositions for analyzing proteins
    10.
    发明授权
    Methods and compositions for analyzing proteins 有权
    用于分析蛋白质的方法和组合物

    公开(公告)号：US07255999B2

    公开(公告)日：2007-08-14

    申请号：US10154042

    申请日：2002-05-21

    申请人： Sharat Singh ,  Hossein Salimi-Moosavi ,  Syed Hasan Tahir ,  Gerald J. Wallweber ,  Hrair Kirakossian ,  Tracy J. Matray ,  Vincent S. Hernandez

    发明人： Sharat Singh ,  Hossein Salimi-Moosavi ,  Syed Hasan Tahir ,  Gerald J. Wallweber ,  Hrair Kirakossian ,  Tracy J. Matray ,  Vincent S. Hernandez

    IPC分类号： G01N33/53 ,  G01N33/533 ,  C12Q1/42

    CPC分类号： G01N33/6842 ,  C07K16/00 ,  C07K2317/40 ,  G01N33/582 ,  G01N33/6803

    摘要： Methods, compositions and kits are disclosed for determining one or more target polypeptides in a sample where the target polypeptides have undergone a post-translational modification. A mixture comprising the sample and a first reagent comprising a cleavage-inducing moiety and a first binding agent for a binding site on a target polypeptide is subjected to conditions under which binding of respective binding moieties occurs. The binding site is the result of post-translational modification activity involving the target polypeptide. The method may be employed to determine the target polypeptide itself. In another embodiment the presence and/or amount of the target polypeptide is related to the presence and/or amount and/or activity of an agent such as an enzyme involved in the post-translational modification of the target polypeptide. The interaction between the first binding agent and the binding site brings the cleavage-inducing moiety into close proximity to a cleavable moiety, which is associated with the polypeptide and is susceptible to cleavage only when in proximity to the cleavage-inducing moiety. In this way, an electrophoretic tag for each of the polypeptides may be released. Released electrophoretic tags are separated and the presence and/or amount of the target polypeptides are determined based on the corresponding electrophoretic tags.

    摘要翻译： 公开了用于确定样品中一种或多种靶多肽已经经历了翻译后修饰的方法，组合物和试剂盒。 包含样品和包含切割诱导部分的第一试剂和用于靶多肽上的结合位点的第一结合剂的混合物经受各自结合部分的结合发生的条件。 结合位点是涉及靶多肽的翻译后修饰活性的结果。 该方法可用于确定靶多肽本身。 在另一个实施方案中，靶多肽的存在和/或量与试剂例如涉及靶多肽的翻译后修饰的酶的存在和/或量和/或活性有关。 第一结合剂和结合位点之间的相互作用使切割诱导部分紧密接近可切割部分，其可与多肽相关，并且仅在接近切割诱导部分时易于切割。 以这种方式，可以释放每个多肽的电泳标签。 分离释放的电泳标签，并且基于相应的电泳标签确定靶多肽的存在和/或量。